Aspira Women's Health Inc. (AWH)
NASDAQ: AWH · Real-Time Price · USD
0.886
-0.014 (-1.56%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States.

The company’s products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1’s high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.

It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis.

The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease.

The company serves physicians, physician office laboratories, and national and regional laboratories.

The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC.

It has a research agreement with Harvard’s Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs and proteins; and a strategic alliance with Quest Diagnostics, Incorporated.

The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women’s Health Inc. in June 2020.

Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.

Aspira Women's Health Inc.
Aspira Women's Health logo
Country United States
Founded 1993
Industry Diagnostics & Research
Sector Healthcare
Employees 64
CEO Nicole Sandford

Contact Details

Address:
Building III, Suite 100
Austin, Texas 78738
United States
Phone 512 519 0400
Website aspirawh.com

Stock Details

Ticker Symbol AWH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000926617
CUSIP Number 04537Y109
ISIN Number US04537Y2081
Employer ID 33-0595156
SIC Code 2835

Key Executives

Name Position
Nicole Sandford CPA Chief Executive Officer, Interim Chief Financial Officer and Director
Dr. Sandra Milligan J.D., M.D. President
John Kallassy Interim Chief Financial Officer
Michelle Snider Senior Vice President of Commercial Strategy and Operations

Latest SEC Filings

Date Type Title
Oct 29, 2024 8-K Current Report
Oct 24, 2024 8-K Current Report
Oct 23, 2024 8-K Current Report
Oct 18, 2024 8-K Current Report
Sep 13, 2024 8-K Current Report
Sep 5, 2024 424B3 Prospectus
Sep 3, 2024 EFFECT Notice of Effectiveness
Aug 28, 2024 UPLOAD Filing
Aug 23, 2024 S-3 Registration statement under Securities Act of 1933
Aug 20, 2024 S-8 Securities to be offered to employees in employee benefit plans